Highest development stage: Phase 3

Development status: Active (as of 2022)

Combination therapy

Mechanism of Action/Target pathogen: Binds irreversibly to beta-lactamases, mainly class A enzymes. No intrinsic antibacterial activity

Additional information: Semisynthetic, derived from tazobactam, similar inhibition profiles to tazobactam. Only available as a combination product, fixed combination with cefepime